Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age
- 9 March 2011
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 29 (12), 2272-2278
- https://doi.org/10.1016/j.vaccine.2011.01.039